Australia
Filter News
Found 8,459 articles
-
Colossal Announces the Tasmania Thylacine Advisory Committee
12/20/2023
Colossal Biosciences, the breakthrough genetic engineering and de-extinction company, is pleased to announce the formation of the Tasmania Thylacine Advisory Committee.
-
Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study
12/19/2023
Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical company specialising in neuroscience drug discovery and early clinical development, is pleased to announce the successful completion of Part B of its Phase 1 comparative trial evaluating the safety and pharmacokinetics of its innovative solid dose prescription cannabidiol (CBD), SAP021.
-
Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program
12/19/2023
Recce Pharmaceuticals Ltd announced it was awarded an Advanced Overseas Finding for $43,774,907 of a synthetic antibiotic Research & Development applicable expenditure by AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science.
-
Opthea Receives A$8.8 million R&D Tax Incentive
12/19/2023
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that it has received an A$8.8 million research and development tax credit from the Australian Taxation Office.
-
Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities
12/18/2023
Propanc Biopharma, Inc. announced that a boutique advisory firm has been engaged to identify strategic investment opportunities primarily to fund the advancement of the Company’s lead product candidate, PRP, to the completion of the Company’s planned Phase I, First-In-Human study in advanced cancer patients suffering from solid tumors.
-
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
12/18/2023
Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS).
-
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea
12/18/2023
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company) today announced positive preclinical results from an in vivo study evaluating the antibacterial efficacy of its lead synthetic anti-infective candidate, RECCE® 327 (R327), against Neisseria gonorrhoeae (N. gonorrhoeae) in a mouse vaginal infection model.
-
Carina Biotech Doses First Patient in Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy
12/18/2023
Carina Biotech Limited (Carina), a cell therapy immuno-oncology company, today announced the dosing of the first patient in a Phase 1/2a clinical trial of its LGR5-targeted CAR-T cell therapy candidate CNA3103 for the treatment of adult patients with metastatic colorectal cancer (mCRC).
-
Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
12/18/2023
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational positron emission tomography (PET) imaging agent TLX250-CDx (Zircaix™,[1] 89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC).
-
Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort
12/18/2023
Azura Ophthalmics Ltd. today announced positive topline efficacy and safety results from a Phase 2 study of AZR-MD-001 in patients with Contact Lens Discomfort (CLD) who could not comfortably wear their lenses as desired and who demonstrated signs of Meibomian Gland Dysfunction (MGD).
-
Interviews can be difficult in any field, but especially in a competitive industry like the life sciences. Read on to discover the best way to answer salary interview questions in our guide.
-
Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP
12/13/2023
Propanc Biopharma, Inc. today announced that the Company’s joint researcher, Mrs. Belén Toledo Cutillas, has commenced an internship at the Cancer Center Amsterdam – vUMC (University Medical Centers).
-
Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change
12/12/2023
Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease, announced its plans to effect.
-
First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent
12/11/2023
Telix Pharmaceuticals Limited today announces that the first patient has been dosed in a United States (U.S.) expanded access program (EAP, ClinicalTrials.gov ID: NCT06090331 ) for TLX250-CDx ( 89 Zr-DFO-girentuximab).
-
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic
12/8/2023
EnGeneIC, an innovative biopharmaceutical company leading the field of armed antibody therapeutics for oncology, has achieved a significant milestone with the granting of FDA “Fast-Track” designation for its pancreatic cancer therapeutic.
-
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
12/7/2023
Immutep Limited is pleased to announce it has received a €1,595,475 research and development tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme.
-
Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01
12/6/2023
Ractigen Therapeutics is excited to announce the submission of a clinical trial application in Australia.
-
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting
12/6/2023
Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company) today announced the presentation of data on the psychometric validity and reliability of SUDS as an outcome measure in assessing anxiety in SAD clinical trials at the 2023 American College of Neuropsychopharmacology Annual Meeting taking place December 3 – 6 in Tampa, Florida.
-
Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
12/6/2023
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces positive topline results from the Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple negative breast cancer (TNBC). Results will be presented today at the 2023 San Antonio Breast Cancer Symposium® (SABCS).
-
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
12/5/2023
Kazia Therapeutics Limited announced the closing of its previously announced purchase and sale of up to an aggregate of 4,444,445 of the Company's American Depositary Shares, each ADS representing ten ordinary shares of the Company, at a purchase price of $0.45 per ADS, in a registered direct offering.